CRT 2018: Late-Breakers Feature Sapien MR, Selution DCB, Low-Risk TAVR, and Radial Access PCI
Executive Summary
You may also be interested in...
MedAlliance Secures $50M To Aid Trials And Commercialization
Trustar Capital’s investment will allow MedAlliance to pursue commercialization of its drug eluting balloon and further its trial efforts.
MedAlliance Brings SELUTION SLR Drug-Eluting Peripheral Balloon To Japan
The Swiss company is rolling out the sirolimus-eluting balloon catheter in Europe and sponsoring trials in the US. The FDA has granted it breakthrough status for three different indications.
Edwards Discontinues Centera TAVR Program As Sapien Sales Continue To Climb
Edwards Lifesciences is giving up on the Centera transcatheter aortic valve replacement (TAVR), despite promising clinical results, to focus on its Sapien TAVR line. The company reported overall revenue of $1.1bn in the second quarter of 2019, representing 14% year-over-year growth, driven by 18% growth in sales of Sapien systems.